Fermenta BiotechQ2 FY22

Fermenta Biotech Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹465.5P/E: 29.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company expects an average revenue growth CAGR of about 15% over the next 5-6 years, which is a conservative estimate averaging out spikes from new projects (Page 6).
  • The premix plant, expected to be operational by end of calendar year 2022, is anticipated to contribute significantly post-marketing period (Pages 9-10).
  • Capacity expansions in vitamin D3 human segment total about 40%, with absorption expected within two years depending on market conditions (Page 14).
  • The animal feed segment's utilization is currently low (30-35%) but expected to recover, contributing to growth (Page 6).
  • New product launches like vegan D3 and vitamin K1 analogs linked to Sayakha project are in progress but may face delay (Page 14).
  • Long-term confidence exists to maintain EBITDA margins at 20-25% with a target of 15% revenue growth while managing product mix and market fluctuations (Pages 11, 17).

See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company mentioned a capex of approximately Rs.35 Crores for the premix plant.
  • This capex is expected to be funded by a mix of internal accruals and debt.
  • No specific mention of new equity fundraising is found in the transcript.
  • Management is cautious about stretching financial bandwidth, indicating measured use of debt.
  • There is no discussion of any new or additional fundraises, either debt or equity, beyond this context.

See what Fermenta Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Construction of a premix plant in Kullu expected to be completed by the end of calendar year 2022 with an estimated capex of Rs.35 Crores.
  • Funding for the premix plant will be a mix of internal accruals and debt.
  • Plans to increase capacity at the Sayakha project for vitamin D3, though no final decision on capex has been taken yet.
  • Focus on launching Vegan D3 made from vegetable oils, prior to advancing vitamin D3 analogs and K1 products.
  • Additional capacity expansions: 25% increase in vitamin D3 human segment capacity recently added, expected to be absorbed over next two years depending on market conditions.
  • Overall strategy involves backward integration for cholesterol manufacturing with focus on secure supply of wool grease.
  • Cautious approach to financial bandwidth to avoid overstretching with multiple ongoing and planned projects.

Track Fermenta Biotech — get its next earnings analysis in your feed

How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisFermenta Biotech
Rev 3Mar 3

How does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →